[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100572900":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":7,"centralContacts":8,"locations":18,"responsibleParty":34,"collaborators":7,"id":36,"slug":7,"hasResults":37,"nctId":38,"briefTitle":39,"officialTitle":40,"acronym":7,"eligibilityCriteria":41,"healthyVolunteers":37,"sex":42,"minAge":43,"maxAge":44,"enrollmentInfo":45,"targetDuration":7,"studyType":48,"phases":7,"briefSummary":49,"conditions":50,"keywords":7,"overallStatus":52,"whyStopped":7,"lastUpdateSubmitDate":53,"lastUpdatePostDateStruct":54,"startDateStruct":57,"completionDateStruct":59,"leadSponsor":61,"locationsCount":62},{"fullName":5,"class":6},"Second Affiliated Hospital of Wenzhou Medical University","OTHER",null,[9,14],{"name":10,"role":11,"phone":12,"phoneExt":7,"email":13},"Yi Jiang","CONTACT","+86-13676715543","1009419972@qq.com",{"name":15,"role":11,"phone":16,"phoneExt":7,"email":17},"Luyan Fang","+86 13806552632","239542008@qq.com",[19],{"facility":20,"status":7,"city":21,"state":22,"zip":23,"country":24,"countryCode":25,"cosmosGeoPoint":26,"geoPoint":31,"contacts":32},"The Second Affiliated Hospital of Wenzhou Medical University","Wenzhou","Zhejiang","325000","China","CN",{"type":27,"coordinates":28},"Point",[29,30],120.66682,27.99942,{"lat":30,"lon":29},[33],{"name":15,"role":11,"phone":16,"phoneExt":7,"email":17},{"type":35,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100572900",false,"NCT06739278","Individual Treatment of Ustekinumab in Perianal Fistulizing Crohn's Disease","Analysis for the Efficacy of Individual Treatment of Perianal Fistulizing Crohn's Disease With Ustekinumab","Inclusion Criteria:\n\n* Clinical diagnosis of Perianal Fistulizing Crohn's Disease\n* Receive ustekinumab therapy\n\nExclusion Criteria:\n\n* Ustekinumab combined with hormones, immunosuppressants, other biologics or small molecule drugs\n* Combined with other autoimmune diseases, such as systemic lupus erythematosus, rheumatoid arthritis, Graves disease, etc.\n* Combined with serious infectious diseases, such as active tuberculosis, EBV infection, cytomegalovirus infection, etc.\n* Combined with malignant tumor\n* Clinical data missing ≥30% or no follow-up","ALL","18 Years","65 Years",{"count":46,"type":47},119,"ESTIMATED","OBSERVATIONAL","This study intends to further explore the actual efficacy of ustekinumab in the individualized treatment of anal fistula Crohn's disease.",[51],"Crohn Disease","NOT_YET_RECRUITING","2024-12-16",{"date":55,"type":56},"2024-12-18","ACTUAL",{"date":58,"type":47},"2024-12-20",{"date":60,"type":47},"2025-01-31",{"name":5,"class":6},1]